FTC

In surprise switch, Bristol-Myers is selling off blockbuster Otezla, promising to complete Celgene acquisition — just later
In surprise switch, Bristol-Myers is selling off blockbuster Otezla, promising to complete Celgene acquisition — just later
Endpoints
Bristol-Myers Squibb
Opdivo
Otezla
M&A
FTC
Celgene
Flag link:
FTC demands could mean months-long delay for Roche-Spark deal
FTC demands could mean months-long delay for Roche-Spark deal
Biopharma Dive
Roche
Spark Therapeutics
FTC
M&A
Flag link:
Investors fret as new regulatory probes spur fresh delays to Roche's $4.3B Spark buyout
Investors fret as new regulatory probes spur fresh delays to Roche's $4.3B Spark buyout
Endpoints
Spark Therapeutics
Roche
FTC
UK
M&A
Flag link:
Judge, CVS witness clash on merger settlement, July hearing set
Judge, CVS witness clash on merger settlement, July hearing set
Biopharma Dive
M&A
CVS Health
Aetna
FTC
Flag link:
Pay-for-delay deals disappearing, FTC says
Pay-for-delay deals disappearing, FTC says
Biopharma Dive
FTC
generics
pay-for-delay
Flag link:
FTC Finds Dwindling Number of Anticompetitive Reverse Payment Deals
FTC Finds Dwindling Number of Anticompetitive Reverse Payment Deals
RAPS.org
FTC
Hatch Waxman Act
anticompetitive practices
Flag link:
Roche delays $4.3B Spark buyout — again — as FTC review drags on
Roche delays $4.3B Spark buyout — again — as FTC review drags on
Endpoints
Roche
Spark Therapeutics
M&A
FTC
Flag link:
Impax in hot water for 'pay-for-delay' deal on Endo painkiller Opana ER, feds say
Impax in hot water for 'pay-for-delay' deal on Endo painkiller Opana ER, feds say
Fierce Pharma
FTC
pay-for-delay
Impax Laboratories
Endo
Amneal
Opana ER
Flag link:
Bristol-Myers Gets FTC Request for More Information on $74 Billion Celgene Deal
Bristol-Myers Gets FTC Request for More Information on $74 Billion Celgene Deal
TheStreet.com
SEC
FTC
M&A
Bristol-Myers Squibb
Celgene
Flag link:
Trump to sign law allowing FTC to scrutinize biosimilar deals
Trump to sign law allowing FTC to scrutinize biosimilar deals
Biopharma Dive
Donald Trump
biosimilars
antitrust
FTC
Flag link:
FTC Clears Takeda's Acquisition of Shire
FTC Clears Takeda's Acquisition of Shire
CP Wire
FTC
M&A
Takeda
Shire
Flag link:
Watch out, Allergan. Activist investor David Tepper won approval to push a shake-up
Watch out, Allergan. Activist investor David Tepper won approval to push a shake-up
Fierce Pharma
investors
Allergan
David Tepper
FTC
Flag link:
The FTC Appeals Shire ViroPharma Dismissal
The FTC Appeals Shire ViroPharma Dismissal
FDA Law Blog
FTC
Shire
ViroPharma
Hatch Waxman Act
Flag link:
Court Dismisses FTC’s Citizen Petition Complaint Against Shire
Court Dismisses FTC’s Citizen Petition Complaint Against Shire
RAPS.org
FTC
citizen petitions
Shire
ViroPharma
Flag link:
FDA chief to big pharma: ‘End the shenanigans’
FDA chief to big pharma: ‘End the shenanigans’
Drug Delivery Business News
FDA
Scott Gottlieb
FTC
generics
competition
Flag link:
Pay-for-Delay Deals: FTC Notes Continued Decline Since SCOTUS Ruling
Pay-for-Delay Deals: FTC Notes Continued Decline Since SCOTUS Ruling
RAPS.org
FTC
pay-for-delay
Supreme Court
Flag link:
How Far Into the Drug Pipeline Should the FTC Reach?
How Far Into the Drug Pipeline Should the FTC Reach?
TheStreet.com
FTC
GSK
Novartis
BRAF inhibitor
MEK inhibitor
melanoma
Array Biopharma
M&A
Flag link:
Pharmaceutical Industry Cannibalization: The Launch of Authorized Generics After the Loss of Market Exclusivity
Pharmaceutical Industry Cannibalization: The Launch of Authorized Generics After the Loss of Market Exclusivity
Xtalks
generics
FDA
FTC
market exclusivity
Flag link:
Mylan hit with antitrust lawsuit over EpiPen device
Mylan hit with antitrust lawsuit over EpiPen device
Mass Device
Mylan Labs
antitrust
EpiPens
drug pricing
FTC
Flag link:
FTC, Endo propose agreement to resolve pay-for-delay dispute
FTC, Endo propose agreement to resolve pay-for-delay dispute
Bizjournals.com
FTC
Endo International
pay-for-delay
Opana ER
lidoderm
Flag link:

Pages